- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Drug
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 262
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Diabetic Retinopathy, Macular Edema
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Retina Vitreous Associates of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Clearwater, Florida • St. Petersburg, Florida
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
- Drug
- Lead sponsor
- Retinal Consultants of Arizona
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 1 more
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
- Interventions
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 89
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Wet AMD
- Interventions
- Lucentis
- Drug
- Lead sponsor
- Retina Institute of Hawaii
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Age-Related Macular Degeneration
- Interventions
- reduced fluence photodynamic therapy with Visudyne, Lucentis
- Drug
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
- Conditions
- Clinically Significant Diabetic Macular Edema
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Philip J. ferrone, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 2
- States / cities
- Great Neck, New York • Hauppauge, New York
- Conditions
- Neurofibromatosis Type 1, Cutaneous Neurofibromas
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Macular Degeneration
- Interventions
- Zifibancimig, Ranibizumab, Port Delivery Platform
- Drug · Device
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 36
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Encino, California + 32 more
- Conditions
- Retinopathy of Prematurity (ROP)
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg
- Drug
- Lead sponsor
- Southern California Desert Retina Consultants, MC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 4
- States / cities
- Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more
- Conditions
- Choroidal Melanoma
- Interventions
- Ranibizumab injection and TTT - ICG based
- Drug
- Lead sponsor
- New England Retina Associates
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Hamden, Connecticut
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Avacincaptad Pegol, Lucentis
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 19 more
- Conditions
- Glaucoma
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
- Interventions
- ranibizumab (Lucentis)
- Drug
- Lead sponsor
- Retina Associates of Cleveland, Inc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Macular Degeneration
- Interventions
- Abicipar Pegol, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 949 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
- Conditions
- Exudative Macular Degeneration
- Interventions
- X-82 oral, ranibizumab (Lucentis)
- Drug
- Lead sponsor
- Tyrogenex
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
- Drug · Device
- Lead sponsor
- Palmetto Retina Center, LLC
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • West Columbia, South Carolina • Houston, Texas
- Conditions
- Rubeosis Iridis, Proliferative Diabetic Retinopathy
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Bhagat, Neelakshi, M.D., M.P.H.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Age Related Macular Degeneration, AMD, CNV
- Interventions
- Efalizumab, Ranibizumab
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glaucoma
- Interventions
- Ranibizumab, Mitomycin (MMC)
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania